Lancashire and South Cumbria
Formulary
 
back
4 Central nervous system

This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net. 

For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/

04-03-04 Other antidepressant drugs

Tryptophan
Formulary

Tablets 500mg

Consultant psychiatrist initiation only

Amber 1 View adult BNF  View SPC online  View childrens BNF
Agomelatine
Formulary

Red with prior approval. LSCFT to approve all applications to use - patients currently on treatment can continue.
Link  MHRA: Agomelatine (Valdoxan): risk of liver toxicity

Red View adult BNF  View SPC online  View childrens BNF
Duloxetine Cymbalta®
Formulary
Capsules 30mg, 60mg

Consultant psychiatrist initiation only
Link  MHRA: Duloxetine: marketed as Cymbalta▼ and Yentreve▼ for different disorders

Amber View adult BNF  View SPC online  View childrens BNF
Mirtazapine
Formulary
Tablets 15mg, 30mg, 45mg
Dispersible tablets 15mg, 30mg, 45mg(only for patients with swallowing difficulties)

Green View adult BNF  View SPC online  View childrens BNF
Reboxetine Edronex®
Formulary

Tablets 4mg

Consultant psychiatrist initiation only

Amber 0 View adult BNF  View SPC online  View childrens BNF
Venlafaxine
Formulary

Tablets 37.5mg, 75mg
M/R capsules 75mg, 150mg

M/R capsules 225mg - to be prescribed as Vencarm XL in primary care
 
Immediate release tablets are first line
Link  MHRA: SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery

Green View adult BNF  View SPC online  View childrens BNF